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Abstract
The epidemiology of Streptococcus pneumoniae, a major cause of meningitis, pneumonia, bacteraemia and acute otitis media in both chil-
dren and adults, has been altered by the availability of the seven-valent pneumococcal conjugate vaccine (PCV7) and selection pressure
from broad-spectrum antibiotics. In Spain, the rates of antimicrobial consumption and resistance are high; of all S. pneumoniae isolates
collected between 2001 and 2003, 9.2% were penicillin-resistant and 26.4% were penicillin-intermediate. These rates were even higher
in children aged £4 years; 52.3% of isolates were penicillin-resistant or penicillin-intermediate. Serogroup 14 comprises nearly 9% of
pneumococcal strains and exhibits the highest resistance to penicillin (69%). Since the introduction of PCV7 in Madrid, the isolates col-
lected from hospitalized children aged <15 years from 21 hospitals revealed that only 8% of cases involving S. pneumoniae isolates were
due to PCV7 serotypes, and no PCV7 vaccination failures were identified. These isolates demonstrated low rates of penicillin–non-sus-
ceptible and erythromycin–non-susceptible strains. Among multiresistant strains, serotype 19A was identified as most important.
Although the recent WHO position paper on childhood immunizations speaks to the growing resistance of pneumococci, antibiotic
resistance in Spain is noted to be decreasing and must be evaluated in conjunction with global studies.
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Introduction
Streptococcus pneumoniae is a major cause of meningitis, pneu-
monia, bacteraemia and acute otitis media in both children and
adults [1,2]. With the widespread availability and overuse of
antibiotics, multidrug-resistant strains of pneumococci have
become increasingly prevalent [3]. The availability of the seven-
valent pneumococcal conjugate vaccine (PCV7) and its incorpo-
ration into national immunization programmes has significantly
reduced both the morbidity and the mortality associated with
pneumococcal disease [4–6]. Both PCV7 and selection pres-
sure from broad-spectrum antibiotics have altered the epidemi-
ology of S. pneumoniae and its various serotypes [7].
The Spanish Experience
The European Antimicrobial Resistance Surveillance System
(http://www.rivm.nl/earss/) documents temporal variations in
antimicrobial resistance, in part to assess the effectiveness of
prevention programmes. The rates of antimicrobial resis-
tance (using previous breakpoints) and antimicrobial con-
sumption in Spain are high. Between 2001 and 2003, system
data documented invasive S. pneumoniae isolated from 1968
Spanish patients, 17.4% of whom were children aged £4 years
[8]. Of all isolates collected, penicillin-resistant strains consti-
tuted 9.2% and penicillin-intermediate strains constituted
26.4%. In children aged £4 years, 52.3% of isolates were
penicillin-resistant or penicillin-intermediate strains. Overall
rates of reduced penicillin susceptibility (resistant plus inter-
mediate) decreased from 39.5% in 2001 to 33% in 2003
(p = 0.05) [8]. The reduction was principally due to changes
noted in children aged £14 years. In this age group, the fre-
quency of reduced penicillin susceptibility decreased from
60.4% in 2001 to 41.2% in 2003 (p = 0.002). Overall anti-
biotic use dropped from 21.66 defined daily doses/1000
inhabitants/day in 1998 to 19.71 defined daily doses/1000
inhabitants/day in 2002 (p <0.001) [8]. In Spain, nearly 9% of
pneumococcal strains are serogroup 14 and have the highest
resistance to penicillin, at 69%, whereas serogroup 3 was
found to be fully susceptible. Strains resistant to penicillin
were often found to be resistant to erythromycin as well [9].
The Surveillance of Antimicrobial Resistance (VIRA; Vigi-
lancia de la Resistencia a los Antimicrobianos) project began
in 2001, with the aim of tracking antimicrobial sensitivity
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patterns of multiresistant bacteria [10,11]. Forty hospitals
from 15 autonomous Spanish communities participated in
this ongoing, epidemiological surveillance project. The num-
ber of penicillin-resistant (minimum inhibitory concentration:
‡2 mg/L) S. pneumoniae isolates decreased significantly from
59.8% in 2001 to 30.2% in 2004 (p <0.0001) to 14.3% in
2006 (p <0.001) [10,11].
Fenoll et al. recently analysed the evolution of antibiotic
non-susceptibility in invasive S. pneumoniae isolates in Spain
after the licensing of respiratory quinolones for adults and
PCV7 for immunization of the paediatric population [12].
During the study period (January 2000 to August 2007;
n = 12,957 isolates), the increase in PCV7 distribution corre-
lated with a decrease in PCV7 serotype prevalence among
invasive isolates in children and adults. This decrease in
PCV7 serotypes correlated with a decrease in penicillin non-
susceptibility in children (r = 0.929; p <0.001) and adults
(r = 0.905; p = 0.002), and with a decrease in erythromycin
non-susceptibility in children (r = 0.833; p = 0.010), suggest-
ing that PCV7 vaccination in children had an indirect (herd)
effect in adults.
The HERACLES study was instituted to assess changes in
pneumococcal serotype distribution, antimicrobial susceptibil-
ity patterns, clinical syndromes, and underlying disease asso-
ciated with invasive pneumococcal disease (IPD) since the
introduction of PCV7 in Madrid, Spain [13,14]. Antimicrobial
susceptibility was determined from invasive pneumococcal
isolates collected from hospitalized children aged <15 years
from 21 Madrid hospitals. Data from the first months (May
2007 to January 2008) of this 3-year epidemiological study
are presented in Tables 1 and 2 [13,14]. Only 8% of cases
with isolation of S. pneumoniae were due to a PCV7 sero-
type, and no PCV7 vaccination failures were identified [14].
The results demonstrated low rates of penicillin-non-suscep-
tible and erythromycin-non-susceptible strains. Serotype 19A
was identified as the most important serotype among multi-
resistant strains [13].
The Autonomous Region of Madrid gave approval for the
use of PCV7 in the childhood vaccination programme in
November 2006, and a surveillance programme has been
established to monitor IPD in all age groups. The serotype
distribution of IPD isolates collected in 2007 is presented in
Table 3. Serotype coverage afforded by PCV7 accounted for
17.5% of the group including all ages, and 7.5% of children
aged <5 years [15].
TABLE 1. Distribution of pneumococcal serotypes causing
invasive pneumococcal disease among hospitalized children
(n = 87). Picazo JJ et al. 6th International Symposium on
Pneumococci and Pneumococcal Diseases, Reykjavik,
Iceland: 8–12 June 2008. Abstract P2-037 [13]
Serotype
No. of
isolates (%) Serotype
No. of
isolates (%)
1 17 (19.5) 11A 1 (1.1)
5 20 (22.9) 17F 2 (2.2)
19A 11 (12.6) 23B 1 (1.1)
7F 8 (9.1) 19Fa 3 (3.4)
3 3 (3.4) 35B 1 (1.1)
8 2 (2.2) 6A 1 (1.1)
14a 2 (2.2) 9Va 2 (2.2)
24B 1 (1.1) 11F 1 (1.1)
24F 5 (5.7) 22F 1 (1.1)
15C 1 (1.1) 41F 1 (1.1)
21 1 (1.1) Non-typed 1 (1.1)
15A 1 (1.1)
aPCV7 serotype.
TABLE 2. Antimicrobial susceptibility in paediatric
Streptococcus pneumoniae isolates after PCV7 (n = 87).
Picazo J et al. Poster presented at the 26th Annual Meeting
of the European Society for Paediatric Infectious Diseases,
Graz, Austria: 13–17 May 2008 [14]
Antibiotic
Resistance
rate (%)
Penicillin (intermediate + resistant) 24.1
19A serotype 43.0
Erythromycin 21.8
cMLSB phenotype 68.4
iMLSB phenotype 15.8
M phenotype 15.8
19A serotype 47.3
Erythromycin + tetracycline 84.2
cMLSB phenotype 75.0
Multidrug-resistant (‡3 antibiotics) 13.8
19A serotype 66.6
cMLSB, constitutive macrolide–lincosamide–streptogramin B; iMLSB, inducible
macrolide–lincosamide–streptogramin B.
TABLE 3. Serotype distribution of invasive Streptococcus
pneumoniae isolates after PCV7 (n = 492). Sanz JC et al.
6th International Symposium on Pneumococci and
Pneumococcal Diseases, Reykjavik, Iceland: 8–12 June 2008.
Abstract P1-O11 [15]
Serotype
Prevalence (%)
All age
groups
Aged
<5 years
Aged
>60 years
1 11.2 17.2
5 11.2 23.7
19A 10.8 15.1 12.7
7F 9.1 9.7 7.6
3 6.7 11.5
8 5.9
14 5.1
6A 3.7 5.1
4 2.8
PCV7, seven-valent pneumococcal conjugate vaccine.
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Conclusions
Pneumococcal infections remain a public health problem all
over the world. The recent WHO position paper on child-
hood immunizations stated that the growing resistance of
pneumococci needs to be addressed by implementing vacci-
nation programmes [13]. The WHO has also stressed the
major public health value provided by vaccines. Although, in
general, antibiotic resistance in pneumococci is increasing,
some interesting trends have been observed in Spain, where
a decrease in resistance has been noted. The interpretation
of these data must be evaluated in conjunction with other
studies. Meanwhile, the efficacy of PCV7 in the reduction of
pneumococcal disease is evident.
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